Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster

Bibliographic Details
Published in:	Signal Transduction and Targeted Therapy
Main Authors:	Harold Marcotte, Lennart Hammarström, Qiang Pan-Hammarström
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-08-01
Online Access:	https://doi.org/10.1038/s41392-022-01146-0

Similar Items

Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants
by: Fanglei Zuo, et al.
Published: (2025-01-01)

Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants
by: Delphine Planas, et al.
Published: (2024-03-01)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
by: Saranya Sridhar, et al.
Published: (2022-10-01)

Clinical characteristics and booster vaccine effectiveness of the Omicron variant
by: Lijun Sun, et al.
Published: (2024-11-01)

Omicron variant: a booster depending on infection histories
by: Jiayu Wang, et al.
Published: (2023-01-01)

Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
by: Ioannis Sitaras, et al.
Published: (2022-11-01)

Co-expression of anti-rotavirus proteins (llama VHH antibody fragments) in Lactobacillus: development and functionality of vectors containing two expression cassettes in tandem.
by: Gökçe Günaydın, et al.
Published: (2014-01-01)

Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity
by: Hassan Abolhassani, et al.
Published: (2021-08-01)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
by: Gen Li, et al.
Published: (2022-07-01)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
by: Weiyu Peng, et al.
Published: (2023-11-01)

Unique DNA repair gene variations and potential associations with the primary antibody deficiency syndromes IgAD and CVID.
by: Steven M Offer, et al.
Published: (2010-08-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
by: Zhongcheng Zhou, et al.
Published: (2022-06-01)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
by: Pai Peng, et al.
Published: (2022-11-01)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
by: Vivek P. Chavda, et al.
Published: (2022-02-01)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
by: Henning Jacobsen, et al.
Published: (2022-10-01)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
by: I-Jung Lee, et al.
Published: (2022-07-01)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
by: Liqiu Jia, et al.
Published: (2022-07-01)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
by: Joy-Yan Lam, et al.
Published: (2022-12-01)

Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies
by: Lei You, et al.
Published: (2025-05-01)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
by: Jinkai Zang, et al.
Published: (2022-06-01)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
by: David N. Springer, et al.
Published: (2023-08-01)

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
by: Frances Priddy, et al.
Published: (2024-12-01)

Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey
by: Haisu Feng, et al.
Published: (2024-08-01)

Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
by: Gudmundur L. Norddahl, et al.
Published: (2022-09-01)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
by: Lei Zhang, et al.
Published: (2023-01-01)

SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects
by: Wang Yating, et al.
Published: (2022-06-01)

Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection
by: Kristin Widyasari, et al.
Published: (2023-08-01)

Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants
by: Rima Moghnieh, et al.
Published: (2022-09-01)

19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern
by: Melissa García-Vega, et al.
Published: (2023-04-01)

Genomic-Based Newborn Screening for Inborn Errors of Immunity: Practical and Ethical Considerations
by: Jovanka R. King, et al.
Published: (2023-04-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Neutralizing Antibodies against 10 SARS-CoV-2 Variants at Two Years Post-COVISHIELD Vaccination with Special Reference to Omicron Subvariants and Booster Administration
by: Rajashree Patil, et al.
Published: (2024-09-01)

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern
by: Sreelekshmy Mohandas, et al.
Published: (2022-05-01)

Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases.
by: Stephan Borte, et al.
Published: (2012-01-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
by: Etsuro Nanishi, et al.
Published: (2022-08-01)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
by: Ranjan K. Mohapatra, et al.
Published: (2022-11-01)

Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
by: Vincent Pavot, et al.
Published: (2023-03-01)

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers
by: Leire Fernández-Ciriza, et al.
Published: (2025-01-01)